Articles On Immutep (ASX:IMM)
Title | Source | Codes | Date |
---|---|---|---|
Market Highlights: Two uttered words that crashed the market, and 5 ASX small caps to watch today
The ASX is set to plunge on Thursday after a crash in New York US Fed unleashed another jumbo 75bp rate hike Fed boss Jerome Powell spooked the markets during his speech The ASX is poised to plunge on Wednesday, tracking movements in Ne... |
Stockhead | IMM | 1 year ago |
ASX increases slightly ahead of today’s rate rise: Aus shares 0.3% higher at noon
ShareCafeASX increases slightly ahead of today’s rate rise: Aus shares 0.3% higher at noon by Peter Milios Last week’s rally for US equities ground to a halt overnight ahead of this week’s Federal Reserve decision on interest rates, as te... |
ShareCafe | IMM | 1 year ago |
Immutep (ASX:IMM) to continue with controlled phase IIB TACTI-003 trial for HNSCC cancer
Immutep (IMM) is given approval by the Independent Data Monitoring Committee (IDMC) to carry on with its planned phase IIb TACTI-003 trialThe IDMC reviewed the initial safety data and concluded that the trial should continue with no modific... |
themarketherald.com.au | IMM | 1 year ago |
Market unfazed by CPI data: ASX finishes 0.18% higher
ShareCafeMarket unfazed by CPI data: ASX finishes 0.18% higher by Peter Milios CPI data from the September quarter has sharply exceeded estimates. As such, multiple banks have made predictions for the next rate rise. Commonwealth Bank (AS... |
ShareCafe | IMM | 1 year ago |
Australian headline inflation hits highest in 32 years: ASX up 0.12% at noon
ShareCafeAustralian headline inflation hits highest in 32 years: ASX up 0.12% at noon by Lauren Hayes The S&P/ASX 200 posted gains this morning as sentiment from Wall Street overnight improved over the Fed potentially turning less agg... |
ShareCafe | IMM | 1 year ago |
ASX Biotech Stocks: Neurotech reports positive paediatric autism results and Arovella to close Perth R&D facility
Neurotech says its NTI164 drug for paediatric autism showed improvements in symptoms Arovella closing Perth R&D facility to focus on invariant Natural Killer T (iNKT) cell platform Argenica reports safety and efficiacy of stroke drug A... |
Stockhead | IMM | 1 year ago |
Energy and Materials only sectors left lagging: ASX closes 0.28% higher
ShareCafeEnergy and Materials only sectors left lagging: ASX closes 0.28% higher by Peter Milios In today’s events, independent commission agency ASIC has launched legal action against BPS Financial, the company behind Gold Coast-based di... |
ShareCafe | IMM | 1 year ago |
Optimism out of the US boosts sentiment: ASX up 0.6% at noon
ShareCafeOptimism out of the US boosts sentiment: ASX up 0.6% at noon by Lauren Hayes Positive gains in the local market have extended into a second day as optimism out of the US about corporate earnings ahead of several key tech reports... |
ShareCafe | IMM | 1 year ago |
Immutep (ASX: IMM) Receives Fast Track Designation from FDA
ShareCafeImmutep (ASX: IMM) Receives Fast Track Designation from FDA Immutep Limited (ASX: IMM) CEO and Executive Director Marc Voigt discusses the FDA fast track designation received in first-line non-small cell lung cancer, the company... |
ShareCafe | IMM | 1 year ago |
Trading Places: Chinese mining giant backs Tietto Minerals and LGI’s new substantial shareholders
Emerging gold miner Tietto Minerals has a new Chinese Mining giant as a substantial shareholder Environment play LGI has new substantial shareholders since listing on the ASX last week Lunnon Metals loses substantial shareholders while Bas... |
Stockhead | IMM | 1 year ago |
ScoPo’s Powerplays: Calmer week for ASX health stocks with some alarming stats about how many people drink instant coffee
During latest period of volatility many health stocks have seen their share prices remain quite stable Several ASX health stocks have rallied this week on positive news including Polynovo on $5 million sales month Telix Pharmaceuticals ral... |
Stockhead | IMM | 1 year ago |
Energy’s advancements just enough to lift the ASX: Aus shares close 2.2% higher
ShareCafeEnergy’s advancements just enough to lift the ASX: Aus shares close 2.2% higher by Peter Milios The ASX’s two-day positive run has turned to three days. It finished the day having increased slightly by 0.03 per cent or 1.80 point... |
ShareCafe | IMM | 1 year ago |
Second fast-track designation for Australian immunotherapy company
Australian immunotherapy company Immutep has secured fast-track designation from the US FDA for its eftilagimod alpha for use in combination with MSD's KEYTRUDA (pembrolizumab). |
BiotechDispatch | IMM | 1 year ago |
Check Up: Blood clots are a $55bn opportunity and these 2 ASX stocks are vying for a slice
Blood clot programs have taken the spotlight recently as new discoveries made Two ASX health stocks are in the blood clot space Top performing ASX healthcare stocks in the past month Blood clots were top of biotech news this week after re... |
Stockhead | IMM | 1 year ago |
Immutep (ASX:IMM) receives FDA Fast Track designation for NSCLC treatment
Immutep (IMM) receives US FDA Fast Track designation for its efti drug candidate as a treatment for non-small cell lung cancer (NSCLC)The designation — Immutep’s second for the drug — is specifically for efti when used in combination with c... |
themarketherald.com.au | IMM | 1 year ago |
ASX Health Stocks: Paradigm soars 19pc after meeting primary endpoint of Phase 2 trial
Paradigm successfully meets primary endpoint of Phase 2 trial Immutep granted Fast Track designation by the FDA ImpediMed signs strategic partnership with GenesisCare Paradigm Biopharma (ASX:PAR) surged 19% this morning after announcing t... |
Stockhead | IMM | 1 year ago |
Why did the Imugene share price implode 31% in September?
The Imugene Limited (ASX: IMU) share price had a rough month despite multiple clinical trial updates. Imugene shares have fallen 30.77% from 26 cents at market close on 31 August to 18 cents at market close on 30 September.... |
Motley Fool | IMM | 1 year ago |
Immutep (ASX:IMM) receives $2.7 million R&D French tax incentive
Immutep (IMM) receives a $2.7 million research and development tax incentive from the French GovernmentThe company received the funds under France’s research tax credit scheme, which sees eligible French companies reimbursed for 30 per cent... |
themarketherald.com.au | IMM | 1 year ago |
Immutep provides clinical update on 'efti' and confirms board appointment
Immutep has provided a clinical development update for its first-in-class LAG-3 antigen-presenting cell, activator product candidate, eftilagimod alpha, and announced a major appointment to its board. |
BiotechDispatch | IMM | 1 year ago |
Immutep (ASX:IMM) initiates new Phase II trial to evaluate efti in soft tissue sarcoma
Immutep (IMM) signs a material transfer agreement with the Maria Skłodowska-Curie National Research Institute of Oncology in Warsaw, PolandThe partnership will enable an investigator-initiated open label Phase II clinical trial to evaluate... |
themarketherald.com.au | IMM | 1 year ago |
ASX Health Stocks: China likes Uscom device, includes it in national emergency guidelines
Uscom’s device is included in China’s emergency guidelines Poland provides grant for Immutep’s Phase 2 trial Medical device company Uscom (ASX:UCM) said that it has been included in the national emergency medicine guidelines for acute hea... |
Stockhead | IMM | 1 year ago |
Evening Report: 30 August, 2022
ShareCafeEvening Report: 30 August, 2022 by Paul Sanger Australian shares have clawed back some of yesterday’s heavy losses despite another slump in global markets over the possibility of more aggressive US and European interest rate hike... |
ShareCafe | IMM | 1 year ago |
Immutep (ASX:IMM) granted new Japanese patent
Immutep (IMM) receives a new patent for its immunotherapy treatment for cancer from the Japanese Patent Office The new patent protects Immutep’s intellectual property relating to combined therapeutic preparations, comprising its lead acti... |
themarketherald.com.au | IMM | 1 year ago |
Lunch Report: 30 August, 2022
ShareCafeLunch Report: 30 August, 2022 by Paul Sanger The ASX had a solid start to the trading session Tuesday, recovering some of yesterday’s material fall. At noon, the S&P/ASX 200 is 0.48 per cent or 33.50 points higher at 6999.00.... |
ShareCafe | IMM | 1 year ago |
Stocks of the Hour: 30 August, 2022
ShareCafeStocks of the Hour: 30 August, 2022 Cobre (ASX:CBE) continues to kick goals, today they announced that their fifth step out drill hole of the ongoing diamond drill programme at the Ngami Copper Project in t... |
ShareCafe | IMM | 1 year ago |
Stocks of the Hour: Cobre, Immutep, AD1 Holdings
30 Aug 2022 - A snapshot of the stocks on the move featuring Cobre (ASX:CBE), Immutep (ASX:IMM) and AD1 Holdings (ASX:AD1). |
FNN | IMM | 1 year ago |
Earnings preview: Here are the ASX shares reporting today
It is the last day of the busiest week in the August earnings season. Thankfully, you can ease into the weekend with far fewer ASX shares set to report their results today. However, there are still a handful of big names that you might wa... |
Motley Fool | IMM | 1 year ago |
Immutep reports new data from phase 2 TACTI-002 trial
Immutep (ASX:IMM) has announced new interim data from lung cancer patients in one of its key clinical trials. The phase 2 TACTI-002 trial is studying the company's LAG-3 Candidate, eftilagimod... |
BiotechDispatch | IMM | 1 year ago |
What’s the outlook for Immutep shares in FY23?
Immutep Ltd (ASX: IMM) shares underperformed in FY22 as markets took a turn for the worse. Most of the previous year’s gains were erased. However, the biotech company has caught a bid in July, as healthcare shares continue to strengthen i... |
Motley Fool | IMM | 1 year ago |
Check Up: US FDA approves first clinical trial of naturally derived psychedelic drugs
US FDA approves the first clinical trial using naturally derived psychedelic drugs It could open possibilities for other clinical trials to follow suit Best and worst biotechs over the past month In a ground-breaking development, the US F... |
Stockhead | IMM | 1 year ago |
What’s the outlook for ASX biotech shares in FY23?
ASX biotech shares incurred heavy losses in FY22 as investors piled out of risk assets and moved into higher-quality corners of the market. Here’s a closer look at three noteworthy ASX biotech shares and their outlook for FY23. CSL Ltd... |
Motley Fool | IMM | 1 year ago |
Why did the Immutep share price plummet 31% last month?
The Immutep Ltd (ASX: IMM) share price plunged lower in June despite the company announcing seemingly good news to the market. As of the final close of last month, the Immutep share price was 29 cents, 30.95% lower than it was at the end o... |
Motley Fool | IMM | 1 year ago |
Here’s how ASX healthcare shares performed in FY22
ASX healthcare shares were a mixed basket this past financial year. After a healthy first half of FY22, the sector took a massive plunge from the restart of trade in January. The S&P/ASX 200 Health Care Index (ASX: XHJ) fell around... |
Motley Fool | IMM | 1 year ago |
Check Up: These biotech themes got billions in VC funding. These ASX stocks could benefit
A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m... |
Stockhead | IMM | 1 year ago |
Evening Report: 6 July, 2022
ShareCafeEvening Report: 6 July, 2022 by Lauren Evans Australian shares spent the afternoon in the red as commodity prices plunged on recession fears. The energy sector tumbled 5.8 per cent, with materials down 5 per cent. Real estate was... |
ShareCafe | IMM | 1 year ago |
ASX Health Stocks: ResApp gets FDA nod, while Japan grants Immutep a patent
ResApp gets clearance from the US FDA Immutep is granted patent in Japan Paradigm Biopharma to commence Phase 3 trial ResApp Health (ASX:RAP) announced that SleepCheckRx has received 510(k) clearance as a prescription-only Software-as-a-M... |
Stockhead | IMM | 1 year ago |
Lunch Report: 6 July, 2022
ShareCafeLunch Report: 6 July, 2022 by Melissa Darmawan The Australian sharemarket has been choppy this morning, trading as low as 0.5 per cent before rebounding to a gain of 0.2 per cent to then fall again. Information technology shares... |
ShareCafe | IMM | 1 year ago |
Immutep (ASX:IMM) granted Japanese patent for IMP761
Immutep (IMM) is granted a Japanese patent for its pre-clinical product candidate, IMP761, valid until 2036 The patent is entitled “Anti-LAG-3 Antibodies” and was granted by the Japanese Patent Office The new patent follows the grant of th... |
themarketherald.com.au | IMM | 1 year ago |
Immutep (ASX:IMM) granted Japanese patent for IMP761
06 Jul 2022 - Immutep (ASX:IMM) has been granted a Japanese patent for its IMP761, an immunosuppressive agonist antibody targeting LAG-3 for autoimmune diseases. |
FNN | IMM | 1 year ago |
Here’s how ASX 200 healthcare shares performed in June
ASX 200 healthcare shares were defensive in June but finished the month down overall. The benchmark S&P/ASX 200 Health Care Index (ASX: XHJ) was volatile, slipping 3% in June. Nevertheless, there were some names worth mentioning. Let’... |
Motley Fool | IMM | 1 year ago |
Own Immutep shares? Here are 3 takeaways from the company’s investor update
Shares of biotech Immutep Ltd (ASX: IMM) have had a hard time this year to date, down 35% since trading resumed in January. At the time of writing, investors are paying 30.5 cents apiece for the Immutep share price. Earlier this month,... |
Motley Fool | IMM | 1 year ago |
I think these 2 ETFs are too good to miss in July 2022
Exchange-traded funds (ETFs) can be very useful for investing in shares. ETFs make it to invest passively, get access to different industries or invest in different geographic markets. One of the most popular ETFs is one that gives access... |
Motley Fool | IMM | 1 year ago |
What’s driving the Immutep share price in June?
The Immutep Ltd (ASX: IMM) share price has gyrated in recent months, having slumped from a 52-week high of 71 cents back in November to close Friday’s session at 37 cents. Investors pushed the stock to 52-week lows by April this year, wh... |
Motley Fool | IMM | 1 year ago |
2022 Has Been Rough for Major Indexes. Here’s Why I’m Not Worried.
This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated. This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated. After rallying from t... |
Motley Fool | IMM | 1 year ago |
Is The Stock Market Going to Crash Again?
This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated. This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated. With the recent infla... |
Motley Fool | IMM | 1 year ago |
ASX shares and inheritances: Survey reveals how Aussies plan to get rich
Men are more likely to invest in ASX shares than women. Thatâs according to a new YouGov survey commissioned by crypto wealth platform Dacxi. The survey also found that men are almost twice as likely to believe theyâll be rich in their... |
Motley Fool | IMM | 1 year ago |
Immutep (ASX:IMM) TACTI-002 data presented at ASCO 2022
ShareCafeImmutep (ASX:IMM) TACTI-002 data presented at ASCO 2022 Immutep Limited (ASX:IMM) Executive Director and CEO Marc Voigt, Chief Scientific and Medical Officer Dr Frédéric Triebel, and Vice President Strategic Development Christia... |
ShareCafe | IMM | 1 year ago |
Australian Broker Call *Extra* Edition – Jun 08, 2022
An additional news report on the recommendation, valuation, forecast and opinion changes for ASX-listed equities. In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now added The Au... |
FNArena | IMM | 1 year ago |
Short & Caught: Flight Centre and rate sensitive stocks among ASX most shorted
In Short & Caught, Stockhead recaps the ASX stocks that are the most shorted and have had the greatest increase in short interest right now. How does shorting work? Shorting works by selling stocks you do not actually own in the hope... |
Stockhead | IMM | 1 year ago |
Immutep reports positive overall response rate in lung cancer trial
Immutep (ASX:IMM) has released new data from the phase 2 lung cancer trial evaluating its lead product candidate eftilagimod alpha in combination with MSD’s anti-PD-1 therapy KEYTRUDA (pembrolizumab) in 114 patients. |
BiotechDispatch | IMM | 1 year ago |